In patients with peripheral artery disease undergoing revascularization, major adverse limb events were more common with ...

Peripheral Artery Revascularization Market has been evolving and changing over the course of past few decades and the market scope has changed a lot over the course of time and to better understand ...

Please provide your email address to receive an email when new articles are posted on . Among patients with peripheral artery disease, the use of vorapaxar appears to reduce peripheral ...

October 9, 2009 (Vienna, Austria) — A reduction in major amputations associated with diabetic foot followed the increased rates of peripheral revascularization that occurred after implementation of ...

In the CARPOOL study, radial-to-peripheral (R2P) access achieved procedural success rates comparable to traditional common ...

Both the incidence and degree of bleeding events after peripheral revascularization match what’s seen for coronary revascularization and for lower-extremity amputation, new findings from the EUCLID ...

In the Losartan Intervention For End point reduction in hypertension (LIFE) study losartan- compared to atenolol-based antihypertensive treatment showed a tendency towards reducing peripheral ...

Treatment with rivaroxaban plus aspirin significantly reduced the risk of major adverse limb and cardiovascular events in the VOYAGER PAD study. A supplemental New Drug Application (sNDA) for ...

Results from the largest real-world propensity-matched comparison to date show that radial-to-peripheral (R2P) access achieves procedural success rates comparable to traditional common femoral artery ...

People who took rivaroxaban (Xarelto) after lower-extremity revascularization for peripheral artery disease (PAD) enjoyed fewer subsequent major adverse limb and cardiovascular events, according to ...

There were tradeoffs for early adopters going the transradial route for infrainguinal peripheral artery intervention, ...